Cardiovascular risk factors in patients with type 2 diabetes: Do we follow the guidelines?

Diabetes Research and Clinical Practice

Volumn 65, Issue 2, 2004, Pages 125-133

  Del Cañizo Gómez, Francisco Javier ^a,c   Moreira Andrés, María Natividad ^b  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c NONE   (Spain)

Author keywords

Cardiovascular risk factors; Coronary artery disease; Dyslipidaemia; Hypertension; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SMOKING HABIT; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GUIDELINES; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 3042513814     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.12.002     Document Type: Article

References (35)

1. The Framingham Heart Study, a general cardiovascular risk profile, Am. J. Cardiol. 38 (1976) 46-51.
2. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., Keen H. Mortality from coronary heart disease and stroke in relation to degree of glicaemia: the Whitehall Study. Br. Med. J. 287:1983;867-870
3. Saydah S.H., Eberhardt M.S., Loria C.M., Brancati F.L. Age and the burden of death attributable to diabetes in the United States. Am. J. Epidemiol. 156:2002;714-719
4. Stern M.P. Glycemia and cardiovascular risk. Diabetes Care. 20:1997;1501-1502
5. Diabetes Drafting Group, Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres, The World Health Organization Multinational Study of Vascular Disease in Diabetics, Diabetologia 28 (Suppl. 1) (1985) 615-640.
6. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:1998;229-234
7. Evans J.M., Wang J., Morris A.D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross-sectional and cohort studies. Br. Med. J. 324:2002;939-942
8. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348:2003;383-393
9. UK Prospective Diabetes Study (UKPDS), Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38), Br. Med. J. 317 (1998) 703-713.
10. Ashwell M., Chinn S., Stalley S., Garrow J.S. Female fat distribution - a simple classification based on two circumference measurements. Int. J. Obes. 6:1982;143-152
11. American Diabetes Association, Standards of medical care for patients with diabetes mellitus, Diabetes Care 26 (Suppl. 1) (2003) S33-S50.
12. WHO, Programme of Nutrition, Family and Reproductive Health Obesity, Preventing and managing the global epidemic, Report of WHO consultation on obesity, Geneva WHO, 1998.
13. George P.B., Tobin K.J., Corpus R.A., Devlin W.H., O'Neill W.W. Treatment of cardiac risk factors in diabetic patients: how well do we follow the Guidelines? Am. Heart J. 142:2001;857-863
14. Spijkerman A.M., Dekker J.M., Nijpels G., et al. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur. J. Clin. Invest. 32:2002;924-930
15. Jovanovic L. Rationale for prevention and treatment of postprandial glucose-mediated toxicity. Endocrinologist. 9:1999;87-92
16. Avignon A., Radauceanu A., Monnier L. Non-fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 20:1997;1822-1826
17. Shaw J.E., Hodge A.M., Courten M., Chitson P., Zimmet P.Z. Isolated post-challenge hyperglycaemic confirmed as a risk factor for mortality. Diabetologia. 42:1999;1050-1054
18. Pyörälä K., Pedersen T.L., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care. 20:1997;614-620
19. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341:1999;410-418
20. Collins R., Armitage J., Parish S., Sleigh P., Peto R. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 patients people with diabetes: a randomized placebo-controlled trial. Lancet. 361:2003;2005-2016
21. Gotto A.M. Jr., Phil D. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am. Heart J. 144:2002;S33-S42
22. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444
23. UK Prospective Diabetes Study (UKPDS) Group, Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39), Br. Med. J. 317 (1998) 713-720.
24. Gerstein H.C. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitors treatment: HOPE and MICRO-HOPE. Diab. Metab. Res. 18:2002;S82-S85
25. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345:2001;851-860
26. Molarius A., Seidell J.C. Selection of anthropometric indicators for classification of abdominal fatness - a critical review. Int. J. Obes. Relat. Metab. Disord. 22:1998;719-727
27. Pouliot M.C., Desprès J.P., Lemieux S., et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. 73:1994;460-468
28. Wilson P.W., D'Agostino R.B., Sullivan L., Parise H., Kannel W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham Experience. Arch. Intern. Med. 162:2002;1867-1872
29. Wilson P.W., Kannel W.B. Obesity, diabetes and risk of cardiovascular disease in the elderly. Am. J. Geriatr. Cardiol. 11:2002;119-123
30. Brochu M., Starling R.D., Tchernoff A., Matthews D.E., García-Rubí E., Poehlman E.T. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J. Clin. Endocrinol. Metab. 85:2000;2378-2384
31. Al-Delaimy W.K., Manson J.E., Solomon C.G., et al. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch. Intern. Med. 162:2002;273-279
32. Jonas M., Reicher-Reiss H., Boyko V., et al. Usefulness of beta-blocker therapy in patients with non-insulin dependent diabetes mellitus and coronary artery disease. Am. J. Cardiol. 77:1996;1273-1277
33. Groop L., Totterman K.J., Harnok G.A. Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Acta Med. Scand. 211:1982;7-12
34. Antiplatelet Trialists' Collaboration, Secondary prevention of vascular disease by prolonged antiplatelet treatment, Br. Med. J. (Clin. Res. Ed.) 296 (1988) 320-331.
35. American Diabetes Association, Aspirin therapy in diabetes, Diabetes Care 26 (Suppl. 1) (2003) S87-S88.